acneiform eruptions/únava

Odkaz je uložen do schránky

ČlánkyKlinické testyPatenty

Vyberte typ řazení

14 Výsledek

A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Purpose: This phase I, open-label, single-arm trial assessed the safety and tolerability of dacomitinib-figitumumab combination therapy in patients with advanced solid tumors.Experimental Design: A standard 3 + 3 dose escalation/de-escalation design was utilized. Starting doses were figitumumab 20

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

To determine the feasible dose and schedule for everolimus, an oral mTOR inhibitor, combined with vinorelbine and trastuzumab for patients with HER2-overexpressing metastatic breast cancer pretreated with trastuzumab. In this phase Ib multicenter, Bayesian dose-escalation study, 50 patients received

Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

BACKGROUND Erlotinib, the epidermal growth factor receptor tyrosine kinase inhibitor, and the intra-venous vinflunine vinca alkaloid microtubule inhibitor have been shown to be effective in the setting of non-small-cell lung cancer (NSCLC) palliative patients with acceptable toxicities. This phase I

Blood polychlorinated biphenyls and manifestation of symptoms in chronic "Yusho" patients.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

The correlation between blood PCB concentration and clinical manifestation of symptoms was investigated in 259 chronic "Yusho" patients, using the information obtained from the nationwide health examination conducted in 1988, twenty years after the outbreak. Concentrations of blood PCBs ranged

[Symptoms and blood PCB level among chronic Yusho patients, twenty-five years after outbreak].

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

To investigate the frequency of symptoms and signs and their relationships with blood PCB (polychlorinated biphenyls) levels, twenty-five years after outbreak, we analyzed the data of 276 Yusho patients (male/female: 137/139) who had received health examination in 1993. For this purpose, 31

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

BACKGROUND The objectives of this phase I study were to determine the safety, pharmacokinetics (PK), pharmacodynamics and efficacy of brivanib combined with full-dose cetuximab in patients with advanced gastrointestinal malignancies. METHODS Patients with advanced gastrointestinal malignancies who

A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

BACKGROUND This phase 2 trial (ClinicalTrials.gov identifier NCT00548093) assessed the efficacy, safety, and impact on health-related quality of life of dacomitinib (PF-00299804), an irreversible tyrosine kinase inhibitor (TKI) of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4,

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

BACKGROUND An open-label, multicenter, single-arm phase II trial was conducted to investigate the clinical activity of dacomitinib in recurrent/metastatic squamous-cell carcinoma of the head and neck (RM-SCCHN). METHODS Eligible patients were administered dacomitinib at 45 mg orally daily, in 21-day

A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

OBJECTIVE To determine antitumor activity of cetuximab monotherapy in patients with refractory metastatic colorectal carcinoma (mCRC) with lack of specific membrane immunostaining for the epidermal growth factor receptor (EGFR). METHODS Patients had immunohistochemical (IHC)-determined mCRC with

Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

BACKGROUND Panitumumab is a fully human, monoclonal antibody against the epidermal growth factor receptor. Previous studies in non-Japanese patients with solid tumors showed that panitumumab exhibited nonlinear pharmacokinetics, was well tolerated (skin toxicities were the most common

[Average of the PCDFs value in blood in patients with Yusho in the 2001 to 2003 fiscal year and comparison between the clinical features and PCDFs].

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

BACKGROUND Kanemi Yusho is the name given to a 1968 food poisoning incident resulting from the ingestion of PCB contaminated rice bran oil that had been used as a heating medium. At the time, victims presented with mainly cutaneous manifestations and various other symptoms such as of the eyes and

An update on Chinese herbal medicines as adjuvant treatment of anticancer therapeutics.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Numerous studies have indicated that in cancer treatment Chinese herbal medicines in combination with chemo-, radio-, or targeted-therapy can be used to enhance the efficacy of and diminish the side effects and complications caused by these therapies. Therefore, an understanding of Chinese herbal

Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Dual inhibition of PI3K and MAPK signaling is conceptually a promising anticancer therapy.This phase 1b trial investigated the safety, maximum tolerated dose (MTD), recommended phase II dose, pharmacokinetics, tumor response, fluorodeoxyglucose positron

Long-Term Health Effects of PCBs and Related Compounds: A Comparative Analysis of Patients Suffering from Yusho and the General Population.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Yusho, which refers to a mass poisoning caused by the ingestion of rice bran oil contaminated with polychlorinated biphenyls, polychlorinated dibenzo-p-dioxins, and polychlorinated dibenzofurans, was first reported in October 1968 in Japan. Yusho patients suffer from various symptoms; however, after

Připojte se k naší
facebookové stránce

Herbal & Natural Medicine

Nejúplnější databáze léčivých bylin podložená vědou

Funguje v 55 jazycích
Bylinné léky podporované vědou
Rozpoznávání bylin podle obrázku
Interaktivní mapa GPS - označte byliny na místě (již brzy)
Přečtěte si vědecké publikace související s vaším hledáním
Hledejte léčivé byliny podle jejich účinků
Uspořádejte své zájmy a držte krok s novinkami, klinickými testy a patenty

Zadejte symptom nebo chorobu a přečtěte si o bylinách, které by vám mohly pomoci, napište bylinu a podívejte se na nemoci a příznaky, proti kterým se používá.
* Všechny informace vycházejí z publikovaného vědeckého výzkumu